BACKGROUND: High mitotic figure count (MFC) correlates with low survival rate in Merkel cell carcinoma (MCC). However, the prognostic impact of histone biomarkers as surrogates of MFC in MCC is unknown. We evaluated the prognostic significance of the immunodetection of mitotic figures and of G2+ tumor nuclei with histone-associated mitotic markers H3K79me3T80ph (H3KT) and phosphohistone H3 (PHH3) in MCC. METHODS: Immunohistochemical analyses of H3KT and PHH3 and proliferative marker Ki-67 were performed in a series of 21 cases of MCC. The significance of the pathologic data and immunoreactivity with these markers was evaluated with Pearson correlation and paired Student t-test. Univariate Cox proportional hazards regression models were performed to assess the relationships between these markers and survival. RESULTS: H3KT detected a higher number of mitotic figure (p<0.0001) and G2+ tumor nuclei (p<0.0052) than did PHH3. Furthermore, the MFC combined with G2+ tumor nuclei detected with H3KT compared to PHH3 and manual MFC was a significant predictor of impaired survival in patients with MCC (p=0.035; HR=1.0172), corresponding to a 1.72% increased risk of death for each unit increase in H3KT. CONCLUSIONS: Biomarker analysis of proliferative rates with histone markers may have relevance in stratifying risk in patients with MCC.
BACKGROUND: High mitotic figure count (MFC) correlates with low survival rate in Merkel cell carcinoma (MCC). However, the prognostic impact of histone biomarkers as surrogates of MFC in MCC is unknown. We evaluated the prognostic significance of the immunodetection of mitotic figures and of G2+ tumor nuclei with histone-associated mitotic markers H3K79me3T80ph (H3KT) and phosphohistone H3 (PHH3) in MCC. METHODS: Immunohistochemical analyses of H3KT and PHH3 and proliferative marker Ki-67 were performed in a series of 21 cases of MCC. The significance of the pathologic data and immunoreactivity with these markers was evaluated with Pearson correlation and paired Student t-test. Univariate Cox proportional hazards regression models were performed to assess the relationships between these markers and survival. RESULTS: H3KT detected a higher number of mitotic figure (p<0.0001) and G2+ tumor nuclei (p<0.0052) than did PHH3. Furthermore, the MFC combined with G2+ tumor nuclei detected with H3KT compared to PHH3 and manual MFC was a significant predictor of impaired survival in patients with MCC (p=0.035; HR=1.0172), corresponding to a 1.72% increased risk of death for each unit increase in H3KT. CONCLUSIONS: Biomarker analysis of proliferative rates with histone markers may have relevance in stratifying risk in patients with MCC.
Authors: Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2010-06-19 Impact factor: 11.527
Authors: Kirsten E Fleming; Thai Yen Ly; Sylvia Pasternak; Marek Godlewski; Steve Doucette; Noreen M Walsh Journal: Hum Pathol Date: 2014-01-08 Impact factor: 3.466
Authors: Sofia Asioli; Alberto Righi; Dario de Biase; Luca Morandi; Virginia Caliendo; Franco Picciotto; Giuseppe Macripò; Francesca Maletta; Ludovica Verdun di Cantogno; Luigi Chiusa; Vincenzo Eusebi; Gianni Bussolati Journal: Mod Pathol Date: 2011-07-15 Impact factor: 7.842
Authors: Einar Gudlaugsson; Ivar Skaland; Emiel A M Janssen; Rune Smaaland; Zhiming Shao; Anais Malpica; Feja Voorhorst; Jan P A Baak Journal: Histopathology Date: 2012-09-11 Impact factor: 5.087
Authors: Tina I Tarantola; Laura A Vallow; Michele Y Halyard; Roger H Weenig; Karen E Warschaw; Travis E Grotz; James W Jakub; Randall K Roenigk; Jerry D Brewer; Amy L Weaver; Clark C Otley Journal: J Am Acad Dermatol Date: 2012-11-27 Impact factor: 11.527
Authors: Sharra L Hammond; Stephanie D Byrum; Sarita Namjoshi; Hillary K Graves; Briana K Dennehey; Alan J Tackett; Jessica K Tyler Journal: Cell Cycle Date: 2013-11-25 Impact factor: 4.534
Authors: Christopher K Bichakjian; Thomas Olencki; Sumaira Z Aasi; Murad Alam; James S Andersen; Rachel Blitzblau; Glen M Bowen; Carlo M Contreras; Gregory A Daniels; Roy Decker; Jeffrey M Farma; Kris Fisher; Brian Gastman; Karthik Ghosh; Roy C Grekin; Kenneth Grossman; Alan L Ho; Karl D Lewis; Manisha Loss; Daniel D Lydiatt; Jane Messina; Kishwer S Nehal; Paul Nghiem; Igor Puzanov; Chrysalyne D Schmults; Ashok R Shaha; Valencia Thomas; Yaohui G Xu; John A Zic; Karin G Hoffmann; Anita M Engh Journal: J Natl Compr Canc Netw Date: 2018-06 Impact factor: 12.693
Authors: Michael T Tetzlaff; Carlos A Torres-Cabala; Penvadee Pattanaprichakul; Ronald P Rapini; Victor G Prieto; Jonathan L Curry Journal: Clin Cosmet Investig Dermatol Date: 2015-01-30
Authors: John Charles Rotondo; Chiara Mazziotta; Carmen Lanzillotti; Mauro Tognon; Fernanda Martini Journal: Int J Mol Sci Date: 2021-10-24 Impact factor: 5.923
Authors: Chiara Mazziotta; Carmen Lanzillotti; Roberta Gafà; Antoine Touzé; Marie-Alice Durand; Fernanda Martini; John Charles Rotondo Journal: Front Oncol Date: 2022-03-08 Impact factor: 6.244
Authors: Ulana Kotowski; Boban M Erović; Julia Schnöll; Victoria Stanek; Stefan Janik; Martin Steurer; Goran Mitulović Journal: Clin Proteomics Date: 2019-12-19 Impact factor: 3.988